SCHEMBL13196869

SCHEMBL13196869

O=C1N=C(Nc2ccc(F)c(F)c2F)S/C1=C\c1ccc2nsnc2c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.36
KMT2A Q03164 5/20 0.36
XDH P47989 1/20 0.36
NPC1 O15118 3/20 0.35
RAB9A P51151 3/20 0.35
CISD1 Q9NZ45 2/20 0.34
PIK3CD O00329 1/20 0.34
CSNK2A2 P19784 1/20 0.34
MAOB P27338 1/20 0.34
PIK3CA P42336 1/20 0.34
PIK3CB P42338 1/20 0.34
MTOR P42345 1/20 0.34
PIK3CG P48736 1/20 0.34
CLK1 P49759 1/20 0.34
CSNK2B P67870 1/20 0.34
CSNK2A1 P68400 1/20 0.34
DYRK1A Q13627 1/20 0.34
DYRK2 Q92630 1/20 0.34
DYRK1B Q9Y463 1/20 0.34
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2789845 1.00 MEN1 (0.36) MEN1KMT2AXDHNPC1RAB9A
SCHEMBL2788310 0.82 PIK3CD (0.47) MEN1KMT2AXDHNPC1RAB9A
SCHEMBL2788313 0.82 PIK3CD (0.47) MEN1KMT2AXDHNPC1RAB9A
SCHEMBL13196946 0.79 KMT2A (0.38) MEN1KMT2AXDHNPC1RAB9A
SCHEMBL2787653 0.75 MEN1 (0.44) MEN1KMT2ARAB9AALOX5POLB
SCHEMBL13196884 0.75 MEN1 (0.44) MEN1KMT2ARAB9AALOX5POLB
SCHEMBL2788626 0.75 CISD1 (0.40) MEN1KMT2AXDHNPC1RAB9A
SCHEMBL13196880 0.75 CISD1 (0.40) MEN1KMT2AXDHNPC1RAB9A
SCHEMBL4768194 0.71 BACE1 (0.36) MEN1KMT2ANPC1RAB9ACISD1
SCHEMBL4245427 0.68 CISD1 (0.38) MEN1KMT2AXDHCISD1CLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7767701-B2 protein serine/threonine kinase inhibitors such as 2-(2-Chloro-5-fluoro-phenylimino)-5-(2,3-dihydro-benzo[1-6]dioxin-6-ylmethylene)-thiazolidin-4-one, used for treating autoimmune diseases, HIV, cancer, anemia myelodysplastic syndrome and thrombocytopenia GLAXOSMITHKLINE LLC (US) 2010-08-03 US disclosed
US-20090023742-A1 THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2009-01-22 US disclosed
US-20090023742-A1 THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2009-01-22 US disclosed
WO-2007103754-A2 THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2007-09-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023742-A1 THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS PIK3CA, BTK, PI4KA MEN1 2870/4885KMT2A 3096/4885XDH 1097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.